Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Leukemia

Free Subscription Articles published in Bone Marrow Transplant Retrieve available abstracts of 135 articles: HTML format

Single Articles

January 2026
1. LOPEZ-PEREIRA P, Bazarbachi A, Marcais A, Ngoya M, et al
   Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.
   Bone Marrow Transplant. 2026 Jan 3. doi: 10.1038/s41409-025-02783.
   PubMed     Abstract available
   
   
   December 2025
2. WETHMAR K, Edinger M, Schafer-Eckart K, Stelljes M, et al
   Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia.
   Bone Marrow Transplant. 2025 Dec 6. doi: 10.1038/s41409-025-02762.
   PubMed     Abstract available
   
   
   
3. BAZARBACHI A, Galimard JE, Abou Dalle I, Labopin M, et al
   Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.
   Bone Marrow Transplant. 2025 Dec 5. doi: 10.1038/s41409-025-02770.
   PubMed     Abstract available
   
   
   
4. BERTAINA A, Maffeis M, Lucchini G, Galimard JE, et al
   Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival - an EBMT PD
   Bone Marrow Transplant. 2025 Dec 1. doi: 10.1038/s41409-025-02748.
   PubMed     Abstract available
   
   
   
5. DI MAJO BE, Abouqateb M, Galimard JE, Dalissier A, et al
   Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP.
   Bone Marrow Transplant. 2025;60:1635-1641.
   PubMed     Abstract available
   
   
   
6. JULLIEN M, Brissot E, Daguindau E, Loschi M, et al
   Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.
   Bone Marrow Transplant. 2025;60:1592-1600.
   PubMed     Abstract available
   
   
   November 2025
7. VILLALBA M, Ferhat AT, Gedde-Dahl T, Socie G, et al
   Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.
   Bone Marrow Transplant. 2025 Nov 29. doi: 10.1038/s41409-025-02751.
   PubMed     Abstract available
   
   
   
8. SANZ J, Ferhat AT, Raiola AM, Blaise D, et al
   Donor selection in PTCy haploidentical transplant for acute lymphoblastic leukemia: a study from the ALWP of the EBMT.
   Bone Marrow Transplant. 2025 Nov 25. doi: 10.1038/s41409-025-02763.
   PubMed     Abstract available
   
   
   
9. AL-ALI RW, Gui G, Ravindra N, Andrew G, et al
   Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia.
   Bone Marrow Transplant. 2025 Nov 24. doi: 10.1038/s41409-025-02757.
   PubMed    
   
   
   
10. BARBULLUSHI K, Labopin M, Kroger N, Finke J, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.
    Bone Marrow Transplant. 2025 Nov 21. doi: 10.1038/s41409-025-02740.
    PubMed     Abstract available
    
    
    October 2025
11. WILLASCH AM, Horgan C, Peters C, Balduzzi A, et al
    Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP.
    Bone Marrow Transplant. 2025 Oct 28. doi: 10.1038/s41409-025-02734.
    PubMed     Abstract available
    
    
    
12. NAGLER A, Galimard JE, Kayser S, Kulagin A, et al
    Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT.
    Bone Marrow Transplant. 2025 Oct 18. doi: 10.1038/s41409-025-02726.
    PubMed     Abstract available
    
    
    
13. NAGLER A, Esteve J, Galimard JE, Sanz J, et al
    Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.
    Bone Marrow Transplant. 2025 Oct 16. doi: 10.1038/s41409-025-02727.
    PubMed     Abstract available
    
    
    
14. YANADA M, Yamasaki S, Mizuno S, Sugita J, et al
    Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Oct 5. doi: 10.1038/s41409-025-02729.
    PubMed     Abstract available
    
    
    
15. MONTORO J, Ferhat AT, Dhedin N, Yakoub-Agha I, et al
    Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMT.
    Bone Marrow Transplant. 2025;60:1309-1315.
    PubMed     Abstract available
    
    
    September 2025
16. MORSINK LM, Keijzer K, Hazenberg CLE, Choi G, et al
    Beneficial effect of PTCy and a short duration of immune suppression on relapse risk in acute myeloid leukemia patients with pretransplant MRD.
    Bone Marrow Transplant. 2025 Sep 19. doi: 10.1038/s41409-025-02716.
    PubMed    
    
    
    
17. RU Y, Chen J, Ferhat AT, Einsele H, et al
    Haploidentical versus matched unrelated donor hematopoietic cell transplantation for adult patients with refractory/relapsed acute lymphoblastic leukemia: a study from the Global Committee and the Acute Leukemia Working Party of the European Society f
    Bone Marrow Transplant. 2025 Sep 15. doi: 10.1038/s41409-025-02708.
    PubMed     Abstract available
    
    
    
18. DACHY G, Labopin M, Socie G, Castilla-Llorente C, et al
    Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML.
    Bone Marrow Transplant. 2025;60:1258-1264.
    PubMed     Abstract available
    
    
    August 2025
19. O'CONNOR TE, Lin C, Roloff GW, Zhang A, et al
    The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02693.
    PubMed     Abstract available
    
    
    
20. LI SQ, Xu LP, Wang Y, Zhang XH, et al
    Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02699.
    PubMed     Abstract available
    
    
    
21. CHAUVET P, Saade C, Demaret J, Beauvais D, et al
    Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis.
    Bone Marrow Transplant. 2025 Aug 21. doi: 10.1038/s41409-025-02700.
    PubMed    
    
    
    
22. CHEN H, Xu LP, Zhang XH, Wang Y, et al
    Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Bone Marrow Transplant. 2025 Aug 18. doi: 10.1038/s41409-025-02698.
    PubMed    
    
    
    July 2025
23. MORALES D, Loth G, Colturato VAR, Tavares RB, et al
    Outcomes of hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia: a multicenter Brazilian cohort study.
    Bone Marrow Transplant. 2025 Jul 24. doi: 10.1038/s41409-025-02676.
    PubMed     Abstract available
    
    
    
24. GUO LP, Hu LJ, Mo XD, Sun YQ, et al
    Characteristics and prognosis of central nervous system relapse after allogeneic hematopoietic stem cell transplantation in adult patients with leukemia.
    Bone Marrow Transplant. 2025 Jul 17. doi: 10.1038/s41409-025-02673.
    PubMed     Abstract available
    
    
    
25. GIEBEL S, Labopin M, Swoboda R, Blaise D, et al
    Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2025 Jul 16. doi: 10.1038/s41409-025-02667.
    PubMed     Abstract available
    
    
    June 2025
26. KWAG D, Yoon JH, Min GJ, Park SS, et al
    Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents.
    Bone Marrow Transplant. 2025 Jun 17. doi: 10.1038/s41409-025-02639.
    PubMed     Abstract available
    
    
    
27. TERAMOTO M, Shimomura Y, Hosoi H, Yanada M, et al
    Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Jun 9. doi: 10.1038/s41409-025-02640.
    PubMed    
    
    
    
28. CAVALLARO G, Lazzarotto D, Pavoni C, Valsecchi F, et al
    Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study.
    Bone Marrow Transplant. 2025 Jun 2. doi: 10.1038/s41409-025-02632.
    PubMed     Abstract available
    
    
    
29. KARAKUS A, Toptas T, Dal MS, Durdu A, et al
    Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias.
    Bone Marrow Transplant. 2025;60:864-872.
    PubMed     Abstract available
    
    
    
30. LI L, Zhu L, Xiong M, Chen Z, et al
    Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older.
    Bone Marrow Transplant. 2025;60:773-778.
    PubMed     Abstract available
    
    
    May 2025
31. NAGLER A, Ferhat AT, Kayser S, Eder M, et al
    Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMT.
    Bone Marrow Transplant. 2025 May 29. doi: 10.1038/s41409-025-02620.
    PubMed     Abstract available
    
    
    
32. MOUKALLED N, Ferhat AT, Bazarbachi A, Blaise D, et al
    Improved outcomes over time in patients aged >/=60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia working party.
    Bone Marrow Transplant. 2025 May 28. doi: 10.1038/s41409-025-02630.
    PubMed     Abstract available
    
    
    
33. ABDUL WAHID SF, Ismail NA, Md Fauzi MF, Mohd Idris MR, et al
    Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia.
    Bone Marrow Transplant. 2025 May 27. doi: 10.1038/s41409-025-02629.
    PubMed    
    
    
    
34. KRAKOW EF, Lee N, Jenkins I, Sala-Torra O, et al
    A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing.
    Bone Marrow Transplant. 2025 May 16. doi: 10.1038/s41409-025-02602.
    PubMed     Abstract available
    
    
    
35. BATTIPAGLIA G, Labopin M, Kulagin A, Versluis J, et al
    Addition of mycophenolate mofetil to a calcineurin inhibitor and post-transplant cyclophosphamide results in lower incidence of extensive chronic graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell transplantation for acute mye
    Bone Marrow Transplant. 2025 May 13. doi: 10.1038/s41409-025-02610.
    PubMed     Abstract available
    
    
    April 2025
36. PERMINOVA M, Shelikhova L, Klimentova M, Skvortsova Y, et al
    Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial.
    Bone Marrow Transplant. 2025 Apr 25. doi: 10.1038/s41409-025-02566.
    PubMed    
    
    
    
37. TARANTINO S, Labopin M, Zeiser R, Stelljes M, et al
    Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02596.
    PubMed     Abstract available
    
    
    
38. BERGLAND BS, Remberger M, Tjonnfjord GE, Vo CD, et al
    Should a young matched unrelated donor be preferred over an older matched related donor in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome?
    Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02579.
    PubMed    
    
    
    
39. GILLE AS, Lenez L, Vanhaesebrouck A, Rivet-Danon D, et al
    First-line chemotherapies administered before hematopoietic cell transplantation in children with acute leukemia: effect on the spermatogonial pool.
    Bone Marrow Transplant. 2025 Apr 17. doi: 10.1038/s41409-025-02547.
    PubMed    
    
    
    
40. ABOU DALLE I, Labopin M, Khvedelidze I, Baron F, et al
    Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party.
    Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02576.
    PubMed    
    
    
    
41. SENAPATI J, Garcia-Manero G, DiNardo CD, Deshmukh I, et al
    Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Apr 11. doi: 10.1038/s41409-025-02590.
    PubMed    
    
    
    
42. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563.
    PubMed    
    
    
    
43. LIU J, Li Y, Zhu F, Lv B, et al
    Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia.
    Bone Marrow Transplant. 2025 Apr 7. doi: 10.1038/s41409-025-02578.
    PubMed    
    
    
    
44. SHIMIZU T, Arai Y, Kondo T, Yano S, et al
    Improved post-transplant outcomes for elderly acute myeloid leukemia patients conditioned with FLU/BU4 rather than conventional MAC regimens.
    Bone Marrow Transplant. 2025 Apr 5. doi: 10.1038/s41409-025-02573.
    PubMed     Abstract available
    
    
    
45. YANADA M, Yamasaki S, Hosoi H, Mizuno S, et al
    Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Apr 5. doi: 10.1038/s41409-025-02585.
    PubMed    
    
    
    
46. SPYRIDONIDIS A, Labopin M, Savani BP, Kulagin A, et al
    The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide.
    Bone Marrow Transplant. 2025;60:499-506.
    PubMed     Abstract available
    
    
    
47. VO PT, Sandmaier BM, Othus M, Ali N, et al
    Relationship between age, conditioning intensity, and outcome after allografting in adults age >/=60 years with AML.
    Bone Marrow Transplant. 2025;60:482-490.
    PubMed     Abstract available
    
    
    March 2025
48. STORCK TN, Morsink LM, Biswana A, Hazenberg CLE, et al
    Donor lymphocyte infusions after HLA-identical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in acute myeloid leukemia patients.
    Bone Marrow Transplant. 2025 Mar 19. doi: 10.1038/s41409-025-02552.
    PubMed    
    
    
    
49. CALVO C, Mornet C, Storey C, Halfon-Domenech C, et al
    Adult height and growth hormone therapy in childhood acute lymphoblastic leukemia survivors treated with total body irradiation and hematopoietic stem cell transplantation before puberty.
    Bone Marrow Transplant. 2025 Mar 3. doi: 10.1038/s41409-025-02532.
    PubMed    
    
    
    
50. ZHOU JY, Chen YX, Yuan HL, Xu YJ, et al
    A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study.
    Bone Marrow Transplant. 2025;60:310-318.
    PubMed     Abstract available
    
    
    February 2025
51. GANG M, Othus M, Sandmaier BM, Davis C, et al
    Modulators of relapse risk in adults allografted for acute myeloid leukemia in measurable residual disease-positive remission.
    Bone Marrow Transplant. 2025 Feb 17. doi: 10.1038/s41409-025-02533.
    PubMed    
    
    
    
52. SANZ J, Labopin M, Versluis J, Blaise D, et al
    Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02527.
    PubMed     Abstract available
    
    
    
53. ZHOU J, Wang F, Yang S, Zhang Y, et al
    Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528.
    PubMed     Abstract available
    
    
    
54. SHAFFER BC, Kebriaei P, de Lima M, Jimenez Jimenez AM, et al
    Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice.
    Bone Marrow Transplant. 2025;60:128-134.
    PubMed     Abstract available
    
    
    
55. GOMEZ-ARTEAGA A, Chokr N, Auletta JJ
    Precision medicine results from equitable representation.
    Bone Marrow Transplant. 2025;60:122-127.
    PubMed     Abstract available
    
    
    January 2025
56. NEUPANE B, Ventura K, Parr K, Lee JR, et al
    Dynamics of neoantigen-specific T-cells in post-transplant relapse: do leukemia neoantigens elicit immune responses in transplant recipients?
    Bone Marrow Transplant. 2025 Jan 29. doi: 10.1038/s41409-025-02515.
    PubMed    
    
    
    
57. OSHIMA S, Arai Y, Kondo T, Yano S, et al
    Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55.
    Bone Marrow Transplant. 2025 Jan 21. doi: 10.1038/s41409-025-02508.
    PubMed     Abstract available
    
    
    
58. BLACKMON AL, Grunwald MR
    Editorial: Molecular MRD testing in patients with acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Jan 11. doi: 10.1038/s41409-024-02493.
    PubMed    
    
    
    December 2024
59. YU F, Niu J, Yang J, Hou J, et al
    Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
    Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500.
    PubMed     Abstract available
    
    
    
60. DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al
    Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Part
    Bone Marrow Transplant. 2024 Dec 19. doi: 10.1038/s41409-024-02499.
    PubMed     Abstract available
    
    
    
61. BLACKMON A, Afkhami M, Yang D, Mokhtari S, et al
    Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.
    Bone Marrow Transplant. 2024 Dec 18. doi: 10.1038/s41409-024-02491.
    PubMed     Abstract available
    
    
    
62. WANG MM, Huang SM, Huang YH, Zhang J, et al
    Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations.
    Bone Marrow Transplant. 2024 Dec 10. doi: 10.1038/s41409-024-02495.
    PubMed    
    
    
    
63. SUN J, Zhang YC, Wei J, Xu YJ, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study.
    Bone Marrow Transplant. 2024 Dec 2. doi: 10.1038/s41409-024-02485.
    PubMed     Abstract available
    
    
    
64. SALAS MQ, Cascos E, Lopez-Garcia A, Perez-Lopez E, et al
    Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC.
    Bone Marrow Transplant. 2024;59:1694-1703.
    PubMed     Abstract available
    
    
    
65. BRUNE M, Kiss T, Anderson H, Nicklasson M, et al
    Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50-70 year old AML patients.
    Bone Marrow Transplant. 2024;59:1676-1682.
    PubMed     Abstract available
    
    
    November 2024
66. MOLINOS-QUINTANA A, Martinez-Cibrian N, Alonso-Saladrigues A, Galan-Gomez V, et al
    Successful allogeneic CD34(+) hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Bone Marrow Transplant. 2024 Nov 17. doi: 10.1038/s41409-024-02473.
    PubMed    
    
    
    
67. LI SQ, Yu CZ, Xu LP, Wang Y, et al
    Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.
    Bone Marrow Transplant. 2024 Nov 16. doi: 10.1038/s41409-024-02466.
    PubMed     Abstract available
    
    
    
68. CHRISTOPHER MR, Nawas MT, Reagan JL
    Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Nov 13. doi: 10.1038/s41409-024-02465.
    PubMed     Abstract available
    
    
    
69. GUI G, Ravindra N, Hegde PS, Andrew G, et al
    Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02447.
    PubMed     Abstract available
    
    
    
70. MA R, Liao Y, Zhang XH, Xu LP, et al
    Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02457.
    PubMed    
    
    
    
71. OTOUKESH S, Yang D, Mokhtari S, Pourhassan H, et al
    Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings.
    Bone Marrow Transplant. 2024;59:1542-1551.
    PubMed     Abstract available
    
    
    October 2024
72. ELGHAWY O, Deshpande S, Sussman J, Garfall A, et al
    Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.
    Bone Marrow Transplant. 2024 Oct 30. doi: 10.1038/s41409-024-02455.
    PubMed     Abstract available
    
    
    
73. GUI G, Ravindra N, Hegde PS, Andrew G, et al
    Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Oct 25. doi: 10.1038/s41409-024-02449.
    PubMed     Abstract available
    
    
    
74. HEGDE PS, Andrew G, Gui G, Ravindra N, et al
    Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Oct 18. doi: 10.1038/s41409-024-02444.
    PubMed    
    
    
    
75. NGO D, Blackmon A, Al Malki MM
    Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation.
    Bone Marrow Transplant. 2024 Oct 8. doi: 10.1038/s41409-024-02425.
    PubMed    
    
    
    August 2024
76. OTHUS M, Baccon D, Ali N, Rodriguez-Arboli E, et al
    Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Aug 29. doi: 10.1038/s41409-024-02407.
    PubMed     Abstract available
    
    
    
77. ZHANG H, Guo W, Wang J, Lu N, et al
    Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Aug 27. doi: 10.1038/s41409-024-02402.
    PubMed     Abstract available
    
    
    
78. SAKAGUCHI H, Taga T, Ishida H, Hama A, et al
    Salvage hematopoietic cell transplantation for children with acute myeloid leukemia relapsed after first transplantation: a Japanese national registry study.
    Bone Marrow Transplant. 2024 Aug 22. doi: 10.1038/s41409-024-02396.
    PubMed    
    
    
    
79. NAGLER A, Labopin M, Salmenniemi U, Wu D, et al
    Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT.
    Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02379.
    PubMed     Abstract available
    
    
    
80. NAGLER A, Labopin M, Swoboda R, Blaise D, et al
    Young (<35 years) haploidentical versus old (>/=35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on
    Bone Marrow Transplant. 2024 Aug 18. doi: 10.1038/s41409-024-02400.
    PubMed     Abstract available
    
    
    
81. MOHTY R, Bazarbachi AH, Labopin M, Esteve J, et al
    Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT.
    Bone Marrow Transplant. 2024 Aug 14. doi: 10.1038/s41409-024-02384.
    PubMed     Abstract available
    
    
    
82. GALLI E, Corrente A, Chiusolo P, Sica S, et al
    CAR-T treatment is safe and effective in adult patients with Down syndrome and B-cell acute lymphoblastic leukemia (B-ALL).
    Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02386.
    PubMed    
    
    
    
83. AL HAMED R, Labopin M, Wu D, Gedde-Dahl T, et al
    Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.
    Bone Marrow Transplant. 2024 Aug 2. doi: 10.1038/s41409-024-02373.
    PubMed     Abstract available
    
    
    July 2024
84. GANZEL C, Wang Y, Roopcharan K, Sun Z, et al
    Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
    Bone Marrow Transplant. 2024 Jul 18. doi: 10.1038/s41409-024-02337.
    PubMed    
    
    
    
85. AHN J, Yoon JH, Kwag D, Min GJ, et al
    Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2024 Jul 12. doi: 10.1038/s41409-024-02363.
    PubMed     Abstract available
    
    
    
86. BUG G, Labopin M, Kulagin A, Blaise D, et al
    Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT).
    Bone Marrow Transplant. 2024 Jul 3. doi: 10.1038/s41409-024-02331.
    PubMed     Abstract available
    
    
    June 2024
87. ZHU J, Xu M, Ye Y, Ru Y, et al
    Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study.
    Bone Marrow Transplant. 2024 Jun 19. doi: 10.1038/s41409-024-02335.
    PubMed    
    
    
    
88. STEINER N, Massoud R, Klyuchnikov E, Gagelmann N, et al
    Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jun 14. doi: 10.1038/s41409-024-02328.
    PubMed     Abstract available
    
    
    
89. ORCHARD K, Langford J, Guy M, Lewis G, et al
    Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jun 12. doi: 10.1038/s41409-024-02317.
    PubMed     Abstract available
    
    
    
90. EL CHEIKH J, Ngoya M, Galimard JE, Remenyi P, et al
    Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party.
    Bone Marrow Transplant. 2024 Jun 4. doi: 10.1038/s41409-024-02300.
    PubMed     Abstract available
    
    
    
91. KUROSAWA S, Shimomura Y, Ishiyama K, Fuse K, et al
    Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study.
    Bone Marrow Transplant. 2024;59:742-750.
    PubMed     Abstract available
    
    
    May 2024
92. GANZEL C, Yating W, Roopcharan K, Sun Z, et al
    Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
    Bone Marrow Transplant. 2024 May 22. doi: 10.1038/s41409-024-02308.
    PubMed     Abstract available
    
    
    
93. TOLOSA-RIDAO C, Suarez-Lledo M, Jimenez-Vicente C, Cortes-Bullich A, et al
    Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia.
    Bone Marrow Transplant. 2024 May 22. doi: 10.1038/s41409-024-02310.
    PubMed    
    
    
    
94. HU X, Wang Z, Qin Y, Xu J, et al
    Allogeneic haematopoietic stem cell transplantation might overcome the poor prognosis of adolescents and adult patients with T-lineage acute lymphoblastic leukaemia and CDKN2 deletion.
    Bone Marrow Transplant. 2024 May 20. doi: 10.1038/s41409-024-02306.
    PubMed     Abstract available
    
    
    
95. MORA E, Montoro J, Balaguer A, Rovira M, et al
    Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298.
    PubMed     Abstract available
    
    
    
96. SINANIDIS I, Hochman MJ, Tsai HL, Randall MP, et al
    Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
    Bone Marrow Transplant. 2024 May 7. doi: 10.1038/s41409-024-02299.
    PubMed    
    
    
    
97. BERNING P, Kolloch L, Reicherts C, Call S, et al
    Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.
    Bone Marrow Transplant. 2024 May 3. doi: 10.1038/s41409-024-02295.
    PubMed     Abstract available
    
    
    
98. BEELEN DW, Iacobelli S, Koster L, Eikema DJ, et al
    Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison.
    Bone Marrow Transplant. 2024;59:670-679.
    PubMed     Abstract available
    
    
    April 2024
99. NAGLER A, Labopin M, Swoboda R, Schroeder T, et al
    Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplanta
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284.
    PubMed     Abstract available
    
    
    
100. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
     Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
     Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
     PubMed    
     
     
     
101. SHEN Y, Liu M, Shen D, Chu M, et al
     Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
     Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280.
     PubMed    
     
     
     
102. FILIOGLOU D, Truscott L, Reddivalla N, Katsanis E, et al
     Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience.
     Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281.
     PubMed    
     
     
     
103. BARANWAL A, Mangaonkar A, Shah MV, Al-Kali A, et al
     EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant.
     Bone Marrow Transplant. 2024;59:558-560.
     PubMed    
     
     
     March 2024
104. MAFFINI E, Labopin M, Kroger N, Finke J, et al
     Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
     Bone Marrow Transplant. 2024 Mar 30. doi: 10.1038/s41409-024-02275.
     PubMed     Abstract available
     
     
     
105. KOO RM, Wong E, Davis JE, Perera T, et al
     A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.
     Bone Marrow Transplant. 2024 Mar 27. doi: 10.1038/s41409-023-02195.
     PubMed    
     
     
     
106. SHANG Q, Bai L, Cheng Y, Suo P, et al
     Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia.
     Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02214.
     PubMed     Abstract available
     
     
     
107. PARK S, Bang SY, Kwag D, Lee JH, et al
     Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
     Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02255.
     PubMed     Abstract available
     
     
     February 2024
108. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
     A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
     Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
     PubMed    
     
     
     
109. YANADA M, Yano S, Kuwatsuka Y, Kawamura K, et al
     The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02222.
     PubMed     Abstract available
     
     
     
110. SPYRIDONIDIS A, Labopin M, Gedde-Dahl T, Ganser A, et al
     Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation.
     Bone Marrow Transplant. 2024;59:217-223.
     PubMed     Abstract available
     
     
     January 2024
111. XIAO M, Zhou J, Zhu X, He Y, et al
     A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2024 Jan 24. doi: 10.1038/s41409-024-02211.
     PubMed     Abstract available
     
     
     
112. CHEN W, Shi J, Luo Y, Yu J, et al
     Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
     Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
     PubMed    
     
     
     
113. ALBINGER N, Muller S, Kostyra J, Kuska J, et al
     Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia.
     Bone Marrow Transplant. 2024 Jan 22. doi: 10.1038/s41409-023-02180.
     PubMed     Abstract available
     
     
     
114. SHARMA A, Galimard JE, Pryce A, Bhoopalan SV, et al
     Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.
     Bone Marrow Transplant. 2024 Jan 15. doi: 10.1038/s41409-024-02197.
     PubMed     Abstract available
     
     
     
115. VELARDI A, Mancusi A, Ruggeri L, Pierini A, et al
     How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia.
     Bone Marrow Transplant. 2024 Jan 11. doi: 10.1038/s41409-024-02199.
     PubMed     Abstract available
     
     
     
116. ARCURI LJ
     Re: Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
     Bone Marrow Transplant. 2024 Jan 10. doi: 10.1038/s41409-023-02186.
     PubMed    
     
     
     
117. SADOWSKA-KLASA A, Zaucha JM, Labopin M, Bourhis JH, et al
     Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.
     Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02192.
     PubMed     Abstract available
     
     
     
118. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
     Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
     Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
     PubMed     Abstract available
     
     
     
119. RAVINDRA N, Dillon LW, Gui G, Smith M, et al
     Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
     Bone Marrow Transplant. 2024 Jan 5. doi: 10.1038/s41409-023-02189.
     PubMed    
     
     
     December 2023
120. ZHANG X, Pang Y, Wei C, Liang D, et al
     Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
     Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
     PubMed    
     
     
     
121. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
     Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
     Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
     PubMed     Abstract available
     
     
     
122. POIRE X, Labopin M, Polge E, Ganser A, et al
     Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype.
     Bone Marrow Transplant. 2023 Dec 13. doi: 10.1038/s41409-023-02167.
     PubMed     Abstract available
     
     
     
123. DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al
     Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT
     Bone Marrow Transplant. 2023 Dec 2. doi: 10.1038/s41409-023-02150.
     PubMed     Abstract available
     
     
     November 2023
124. CAO LQ, Huo WX, Zhang XH, Xu LP, et al
     Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients.
     Bone Marrow Transplant. 2023 Nov 15. doi: 10.1038/s41409-023-02117.
     PubMed     Abstract available
     
     
     
125. HARBI S, Brac de la Perriere L, Bouchacourt B, Garciaz S, et al
     Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.
     Bone Marrow Transplant. 2023 Nov 3. doi: 10.1038/s41409-023-02134.
     PubMed     Abstract available
     
     
     October 2023
126. YANG L, Lai X, Yang T, Lu Y, et al
     Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
     Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02137.
     PubMed     Abstract available
     
     
     
127. HUANG J, Feng B, Cheng Y, Xu L, et al
     Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center study.
     Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02141.
     PubMed    
     
     
     
128. CANCIO M, Troullioud Lucas AG, Bierings M, Klein E, et al
     Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia.
     Bone Marrow Transplant. 2023 Oct 17. doi: 10.1038/s41409-023-02121.
     PubMed     Abstract available
     
     
     
129. CHO C, Devlin S, Maloy M, Horowitz MM, et al
     Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis.
     Bone Marrow Transplant. 2023;58:1089-1095.
     PubMed     Abstract available
     
     
     September 2023
130. SATTY AM, Klein E, Mauguen A, Kunvarjee B, et al
     T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML.
     Bone Marrow Transplant. 2023 Sep 29. doi: 10.1038/s41409-023-02113.
     PubMed     Abstract available
     
     
     
131. CAO Y, Zhang C, Zhao X, Huang J, et al
     Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China.
     Bone Marrow Transplant. 2023 Sep 20. doi: 10.1038/s41409-023-02106.
     PubMed    
     
     
     
132. HARADA N, Okamura H, Makuuchi Y, Kuno M, et al
     Third HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide for relapsed acute leukemia.
     Bone Marrow Transplant. 2023 Sep 15. doi: 10.1038/s41409-023-02108.
     PubMed    
     
     
     
133. NAGLER A, Labopin M, Kroger N, Schroeder T, et al
     The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT.
     Bone Marrow Transplant. 2023 Sep 2. doi: 10.1038/s41409-023-02095.
     PubMed     Abstract available
     
     
     
134. JENG MY, Kong D, Rajalingam R, Lin RJ, et al
     Lack of disease control remains a major barrier to transplant for older patients with AML.
     Bone Marrow Transplant. 2023;58:1054-1056.
     PubMed    
     
     
     August 2023
135. REY G, Daguenet E, Bonjean P, Devillier R, et al
     Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC.
     Bone Marrow Transplant. 2023 Aug 31. doi: 10.1038/s41409-023-02082.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.